Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.
Ashish Saxena, MD, PhD, assistant attending physician, NewYork-Presbyterian Hospital, assistant professor of medicine, Weill Cornell Medical College, discusses the future of next-generation ALK inhibitors in non—small cell lung cancer (NSCLC).
Alectinib (Alecensa) and brigatinib (Alunbrig) have not been compared in a head-to-head clinical trial, says Saxena.
It appears that brigatinib has a higher sensitivity to certain resistance mutations versus alectinib, adds Saxena. However, it is unknown whether that translates to a longer progression-free survival.
The question of what to give patients who progress on a second-line ALK inhibitor like lorlatinib (Lorbrena) remains an area of active investigation, explains Saxena. Likely, chemotherapy would be the optimal option; however, potential novel agents and combination strategies are under evaluation.